文献

1. Wiesel LL, Barritt AS, Stumpe WM. The synergistic action of para-aminobenzoic acid and cortisone in the treatment of rheumatoid arthritis. Am J Med Sci 1951;222:243–8.
2. Willis I, Kligman AM. Aminobenzoic acid and its esters. The quest for more effective sunscreens. Arch Dermatol 1970;102:405–17.
3. Sieve BF. The clinical effects of a new B-complex factor, para-aminobenzoic acid, on pigmentation and fertility. South Med Surg 1942(March);104:135–9.
4. Zarafonetis CJD. The treatment of scleroderma: results of potassium para-aminobenzoate therapy in 104 cases. In: Mills LC, Moyer JH eds. Inflammation and Diseases of Connective Tissue. Philadelphia: W. B. Saunders Co. 1961, 688–96.
5. Zarafonetis CJD, Dabich L, Negri D, et al. Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survival. J Clin Epidemiol 1988;41:193–205.
6. Zarafonetis CJ, Dabich L, Devol EB, et al. Retrospective studies in scleroderma: pulmonary findings and effect of potassium p-aminobenzoate on vital capacity. Respiration 1989;56:22–33.
7. Clegg DO, Reading JC, Mayes MD, et al. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. J Rheumatol 1994;21:105–10.
8. Grace WJ, Kennedy RJ, Formato A. Therapy of scleroderma and dermatomyositis. NY State J Med 1963;63:140–4.
9. Zarafonetis CJD. Treatment of Peyronie’s disease with potassium para-aminobenzoate. J Urol 1959;81:770–2.
10. Zarafonetis CJD, Curtis AC, Shaw JM. Treatment of pemphigus with potassium para-aminobenzoate. Am J Med Sci 1956;231:30–50.
11. Sieve BF. Further investigations in the treatment of vitiligo. Virginia Med Monthly 1945(January):6–17.
12. Hughes CG. Oral PABA and vitiligo. J Am Acad Dermatol 1983;9:770 [letter].
13. Gaby AR. The story of PABA. Nutr Healing 1997;March:3–4, 11 [review].
14. Zarafonetis CJD. Darkening of gray hair during para-amino-benzoic acid therapy. J Invest Dermatol 1950;15:399–401.
15. Kantor GR, Ratz JL. Liver toxicity from potassium para-aminobenzoate. J Am Acad Dermatol 1985;13:671–2.
16. Hughes CG. Oral PABA and vitiligo. J Am Acad Dermatol 1983;9:770 [letter].
17. Worobec S, LaChine A. Dangers of orally administered para-aminobenzoic acid. JAMA 1984;251:2348.
18. Zarafonetis CJD, Grekin RH, Curtis AC, et al. Further studies on the treatment of lupus erythematosus with sodium para-aminobenzoate. J Invest Dermatol 1948;11:359.

• 
• 
• 
• 
• 
• 
• 
• 
• 
• 

• 
• 
• 
• 
• 
• 
• 
• 

• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
•